US-based consumable medical devices maker SunMed has agreed to buy Vyaire Medical’s respiratory and anaesthesia consumables business unit.

The financial terms of the deal were not disclosed.

The consumables division of Vyaire Medical produces and markets a range of consumables with a focus on airway management and operative care. The brands involved in the deal are AirLife oxygen therapy, SuperNO2VA nasal PAP ventilation, and Vital Signs anaesthesia circuits among others.

Vyaire Medical CEO Gaurav Agarwal said: “This divestiture allows Vyaire to focus on its industry-leading respiratory diagnostics and ventilation businesses and accelerate our strategic growth plans.

“Uniting the industry-leading Vyaire consumables portfolio with SunMed’s compatible suite of products is a win-win for both companies, as well as customers and patients, and will enhance the potential for long-term growth of the combined consumables portfolio.”

SunMed said that post-acquisition, the enlarged entity will aim to increase innovation and maintain reliable and predictable product supply.

The enlarged business is also expected to act as a one-stop source for the consumable respiratory and anaesthesia products, said the Frazier Healthcare Partners-backed firm.

The deal will combine a range of consumables products from both companies to offer a broader portfolio of products for practitioners, first responders, hospitals, and home care.

According to SunMed, the addition of Vyaire Medical’s North American facility will ensure fast, accurate and reliable product delivery.

The combined entity will help enhance SunMed’s manufacturing capabilities. After the closing of the deal, SunMed will have a scaled platform spread across 250,000ft2 of manufacturing space.

Additionally, the acquisition will enable the consumable medical devices maker to enter new markets with strong sales presence and boost its global distribution network.

SunMed CEO Hank Struik said: “This combination represents an exciting growth opportunity for SunMed that will strengthen our already robust core consumables business and further differentiate our ability to meet our customers’ needs.

“The transaction brings together two like-minded teams who share a deep commitment to quality, reliability and continuous innovation as trusted partners to healthcare professionals.”

Expected to close in the first half of this year, the deal is subject to customary conditions and regulatory approvals.